A total of 11 Russian pharmaceutical industry organizations uniting drug manufacturers, distributors, pharmacy organizations and the patient community wrote a collective letter addressed to Vladimir Putin, President of the Russian Federation, drawing his attention to the unwillingness to launch the industrial operation of the monitoring system drug movements and provide arguments why it is necessary to postpone the start, scheduled for July 1, 2020.
The situation surrounding COVID-19 required drug manufacturers and the entire supply chain to the patient to focus unprecedented efforts, primarily on the development of drugs against COVID-19 and ensuring the uninterrupted supply of drugs for the healthcare system and the population of the Russian Federation.
“It is for the reasons of global force majeure that the current degree of readiness of the drug labeling system and the entire supply chain, according to our professional estimates, does not now guarantee the uninterrupted supply of drugs as one of the key factors of social stability in these conditions,” the letter says.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze